Spots Global Cancer Trial Database for EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors

Official Title: Endoscopic Ultrasound-guided Fine-needle Injection for Multiple Endocrine Neoplasia Type 1-related Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study

Study ID: NCT05554744

Conditions

Multiple Endocrine Neoplasia Type 1

Pancreatic Neuroendocrine Tumor

Interventions

EUS-guided fine-needle injection

Study Description

Brief Summary: The present study aims to evaluate the feasibility, safety and efficacy of EUS-FNI for MEN1-related pNETs

Detailed Description: The management of multiple endocrine neoplasia type 1 (MEN1-1)-related pancreatic neuroendocrine tumors (pNETs) remains controversial. In general, surgical resection is currently the first-line therapy for MEN1-1-related pNETs. However, the surgical resection of pNETs is conditional for specific patients, and the incidence of postoperative adverse events is still high. Recently, several studies have demonstrated that endoscopic ultrasonography (EUS)-guided fine-needle injection (EUS-FNI) with ethanol or lauromacrogol may provide an alternative to surgical resection of pNETs. Nevertheless, their sample size was relatively small and conclusions were drawn based on short-term results. Therefore, a multicenter prospective study is being performed to further access the efficacy and safety of EUS-FNI for MEN1-1-related pNETs.